Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI could spot lung cancer in Non-Smokers with family history

NCT ID NCT06295497

Diagnosis Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether an artificial intelligence program can help detect lung cancer early in non-smokers aged 50 to 75 who have a close family member with lung cancer. About 3,000 participants will get a low-dose CT scan of their chest, and the AI will analyze the images for suspicious nodules. If the AI finds a nodule, doctors will follow up to check if it is cancer. The goal is to see if AI can make lung cancer screening practical and accurate for this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artificial intelligence software (Lung-SIGHT) to analyze low-dose CT scans
What this could lead to
If successful, this could provide a practical, AI-driven screening method to detect lung cancer early in non-smokers with a family history, potentially saving lives through earlier treatment.
What could go wrong
This is an early feasibility study with no control group, so results may not prove the AI is better than standard care. The AI might miss some cancers or flag too many false alarms, leading to unnecessary procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients are eligible to be included in the study only if all of the following criteria apply: 1. Age 50-75 years old 2. Non-smoker (defined as less than 100 cigarettes in lifetime) 3. Having a first-degree family history of lung cancer 4. Physically fit for curative treatment if early-staged lung cancer is found 5. Able to provide written informed consent 6. Consent to follow up visits and follow up CT scan if indicated 7. Consent to blood taking for translational research Exclusion Criteria: Patients who meet any of the following exclusion criteria at screening are not eligible to be enrolled in this study: 1. History of malignancy 2. Smoking history (defined as more than 100 cigarettes in lifetime) 3. Clinical symptoms suspicious for lung cancer e.g. haemoptysis, chest pain, weight loss 4. Medical comorbidities that preclude curative treatment (surgery) for lung cancer, such as severe heart disease, acute or chronic respiratory failure, home oxygen therapy, bleeding disorder 5. Pregnant ladies or ladies planning for conception 6. History of tuberculosis or interstitial lung disease 7. Pneumonia requiring antibiotic treatment within the last 12 weeks 8. CT thorax or chest performed within 2 years (including LDCT, PET-CT, MRI thorax or suspicious of lung cancer) 9. Unable or unwilling to provide written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Clinical Oncology, Prince of Wales Hospital

    RECRUITING

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.